In today’s podcast, Crinetics co-founders Dr. Scott Struthers and Dr. Steve Betz share their views and experiences in drug discovery and development, revealing what it really takes to bring a new medication from concept to patients.
Acromegaly
Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
Another great support resource for people with acromegaly
October 27, 2022
We take advantage of Acromegaly Day, coming up on November 1, to highlight resources from industry partners. The Pfizer Patient Affairs Liaisons (PALs) connect patients and caregivers affected by rare conditions with programs and information. PALs work with
Acromegaly: A Rational Approach to Medical Management of Patients with Residual and Recurrent Disease.
March 24, 2022
This is a highly informative presentation on the subtleties of the medical management of this complicated disease direct from the clinical practices of one of the best most experienced physicians treating acromegaly patients today.
Supporting a new diagnosis of Acromegaly
January 4, 2022
We continue to showcase Pfizer’s new series on patient support. This brochure offers great advice on how to deal with a new acromegaly diagnosis. The materials provide valuable content given the importance of proper disease
When 304 people, including 128 living with acromegaly, gather to talk about the disease, good things can happen.
November 16, 2021
In January 2021, the Acromegaly Community, a US-based patient advocacy organization, organized and participated in an externally lead patient focus drug development meeting. The EL-PFDD initiative is a Food and Drug Administration (FDA) effort to systematically
Acromegaly: the last 30 years
October 29, 2021
In this Podcast, Dr. Blevins gives us a perspective of the last 30 years on the developments in this field. Like many other conditions, the advances in therapy, imaging, surgery techniques, diagnostic testing, and clinical knowledge have been nothing short of remarkable.
Canada to Mexico: Rare pituitary disease patient bikes the 1845-mile Pacific Coast Highway
August 13, 2021
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.
A new drug for acromegaly: an insider’s look at the clinical trial
July 26, 2021
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.
A Conversation with Acromegaly Patient Advocates
July 19, 2021
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.
Big news for acromegaly at Crinetics
July 12, 2021
From the desk of J D Faccinetti – co-founder – The company recently kicked off a phase 3 trial for their new nonpeptide oral drug for acromegaly and announced the dosing of their first acromegaly
Pregnancy and acromegaly
June 17, 2021
Acromegaly: what to do with medical treatment during pregnancy and the options available today.
The ride for acromegaly
June 8, 2021
From Jorge D. Faccinetti – co-founder. With a pituitary disease like acromegaly, Cushing’s, hypopituitarism, and others, or for that matter, any other chronic condition, a big part of the battle is to get up every
Two clinical trials for acromegaly patients: see if you are eligible.
May 10, 2021
Camurus AB, a pharmaceutical company based in Lund, Sweeden, is currently recruiting volunteers for two clinical trials on the long-term safety and efficacy of an octreotide subcutaneous depot to treat acromegaly. This new treatment offers